Last reviewed · How we verify
Taltz
Taltz is a Small molecule drug developed by Yale University. It is currently FDA-approved for Ankylosing spondylitis, Erythrodermic psoriasis, Non-radiographic axial spondyloarthritis. Also known as: Ixekizumab.
Taltz, also known as ixekizumab, is a humanized monoclonal antibody that binds and neutralizes interleukin 17A, reducing inflammation. It is used to treat autoimmune diseases, including psoriasis and psoriatic arthritis, as indicated by clinical trials registered on ClinicalTrials.gov.
At a glance
| Generic name | Taltz |
|---|---|
| Also known as | Ixekizumab |
| Sponsor | Yale University |
| Target | Interleukin-17A |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Erythrodermic psoriasis
- Non-radiographic axial spondyloarthritis
- Plaque psoriasis
- Psoriatic arthritis
- Pustular psoriasis
Common side effects
- Adverse events (overall)
- Infections
- Injection site reactions
- Upper respiratory tract infections
- Nausea
- Tinea infections
- Rhinitis
- Oral candidiasis
- Urticaria
- Influenza
- Conjunctivitis
- Inflammatory bowel disease
Serious adverse events
- Serious adverse events (overall 0-60 weeks)
- Serious adverse events (maintenance period)
- Serious infections
Key clinical trials
- A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (PHASE3)
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) (PHASE4)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Psoriasis Longitudinal Assessment and Registry
- Proactive TDM Versus Standard Use of Biologics in Psoriasis (PHASE4)
- Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis (NA)
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taltz CI brief — competitive landscape report
- Taltz updates RSS · CI watch RSS
- Yale University portfolio CI
Frequently asked questions about Taltz
What is Taltz?
What is Taltz used for?
Who makes Taltz?
Is Taltz also known as anything else?
What development phase is Taltz in?
What are the side effects of Taltz?
What does Taltz target?
Related
- Target: All drugs targeting Interleukin-17A
- Manufacturer: Yale University — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Erythrodermic psoriasis
- Indication: Drugs for Non-radiographic axial spondyloarthritis
- Also known as: Ixekizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing